Drug intelligence / Profile preview

M9466 + irinotecan

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

M9466 + irinotecan is an investigational combination therapy being evaluated in advanced solid tumors and colorectal cancer. M9466 is an oral PARP1 inhibitor (poly[ADP-ribose] polymerase 1 inhibitor) designed to inhibit DNA repair in tumor cells, thereby enhancing the cytotoxic effect of chemotherapeutic agents. Irinotecan is a topoisomerase 1 inhibitor that interferes with DNA replication and transcription by causing DNA strand breaks. The combination is studied to exploit potential synergy through dual impairment of DNA repair pathways, potentially improving anti-tumor activity in patients for whom standard therapies have failed.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on M9466 + irinotecan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M9466 + irinotecan.

Explore the full profile